Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …

Purpose Germline mutations in DNA damage repair (DDR) genes are identified in a
significant proportion of patients with metastatic prostate cancer, but the clinical implications …

Purpose The prevalence of homologous recombination DNA damage repair (HR-DDR)
deficiencies among all tumor lineages is not well characterized. Therapy directed toward …

Background Prostate cancer is a heterogeneous disease, but current treatments are not
based on molecular stratification. We hypothesized that metastatic, castration-resistant …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

Background BRCA1 and BRCA2 mutations have been associated with prostate cancer
(PCa) risk but a wide range of risk estimates have been reported that are based on …